{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:28:32Z","timestamp":1791912512424,"version":"4.3.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.cld.2021.06.004","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T23:08:27Z","timestamp":1627513707000},"page":"741-762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Controversies in Treating Chronic HBV"],"prefix":"10.1016","volume":"25","author":[{"given":"Phunchai","family":"Charatcharoenwitthaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apichat","family":"Kaewdech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerha","family":"Piratvisuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10003","key":"10.1016\/j.cld.2021.06.004_bib1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2021.06.004_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antiviral Res"},{"issue":"7","key":"10.1016\/j.cld.2021.06.004_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri2314","article-title":"Interferon-inducible antiviral effectors","volume":"8","author":"Sadler","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.cld.2021.06.004_bib7","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1128\/JVI.74.9.4165-4173.2000","article-title":"Intrahepatic induction of alpha\/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice","volume":"74","author":"Wieland","year":"2000","journal-title":"J\u00a0Virol"},{"issue":"18","key":"10.1016\/j.cld.2021.06.004_bib8","doi-asserted-by":"crossref","first-page":"9332","DOI":"10.1128\/JVI.00918-10","article-title":"Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus","volume":"84","author":"Xu","year":"2010","journal-title":"J\u00a0Virol"},{"issue":"13","key":"10.1016\/j.cld.2021.06.004_bib9","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1128\/JVI.00236-10","article-title":"Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S\/S RNAs","volume":"84","author":"Li","year":"2010","journal-title":"J\u00a0Virol"},{"issue":"Suppl 4","key":"10.1016\/j.cld.2021.06.004_bib10","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.1093\/cid\/ciw023","article-title":"Mechanism of hepatitis B virus persistence in hepatocytes and its carcinogenic potential","volume":"62","author":"Dandri","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"issue":"26","key":"10.1016\/j.cld.2021.06.004_bib13","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cld.2021.06.004_bib14","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"issue":"9454","key":"10.1016\/j.cld.2021.06.004_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/0003-4819-142-4-200502150-00006","article-title":"A\u00a0randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone","volume":"142","author":"Chan","year":"2005","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2021.06.004_bib18","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.23568","article-title":"Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen\u2013positive chronic hepatitis B","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2021.06.004_bib19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0016-5085(93)90903-P","article-title":"Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B","volume":"105","author":"Brunetto","year":"1993","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/hep.1840150405","article-title":"A\u00a0randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg","volume":"15","author":"Fattovich","year":"1992","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib21","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/jhep.2003.50148","article-title":"Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy","volume":"37","author":"Lampertico","year":"2003","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2021.06.004_bib22","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/hep.510260634","article-title":"A\u00a0randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum","volume":"26","author":"Lampertico","year":"1997","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"12","key":"10.1016\/j.cld.2021.06.004_bib23","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cld.2021.06.004_bib24","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","article-title":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/gutjnl-2011-301430","article-title":"Randomised study comparing 48 and 96\u00a0weeks peginterferon \u03b1-2a therapy in genotype D HBeAg-negative chronic hepatitis B","volume":"62","author":"Lampertico","year":"2013","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1128\/jvi.52.2.396-402.1984","article-title":"Large surface proteins of hepatitis B virus containing the pre-s sequence","volume":"52","author":"Heermann","year":"1984","journal-title":"J\u00a0Virol"},{"issue":"3","key":"10.1016\/j.cld.2021.06.004_bib27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/v9030056","article-title":"Complete and incomplete hepatitis B virus particles: formation, function, and application","volume":"9","author":"Hu","year":"2017","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/v12020126","article-title":"Hepatitis B virus (HBV) subviral particles as protective vaccines and vaccine platforms","volume":"12","author":"Ho","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3748\/wjg.v13.i1.65","article-title":"Hepatitis B virus morphogenesis","volume":"13","author":"Bruss","year":"2007","journal-title":"World J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2021.06.004_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/liv.12403","article-title":"HBsAg quantification: useful for monitoring natural history and treatment outcome","volume":"34","author":"Martinot-Peignoux","year":"2014","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/17474124.2014.876362","article-title":"Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility","volume":"8","author":"Hadziyannis","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12072-015-9644-y","article-title":"Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis","volume":"9","author":"Peng","year":"2015","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3851\/IMP3304","article-title":"Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data","volume":"24","author":"Pavlovic","year":"2019","journal-title":"Antivir Ther"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cis859","article-title":"Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response","volume":"56","author":"Sonneveld","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2021.06.004_bib35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/liv.12998","article-title":"Virological and serological tools to optimize the management of patients with chronic hepatitis B","volume":"36","author":"Martinot-Peignoux","year":"2016","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.cld.2021.06.004_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jvh.12467","article-title":"A\u00a0randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: role of host and viral factors associated with treatment response","volume":"23","author":"Tangkijvanich","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12072-011-9280-0","article-title":"Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients","volume":"7","author":"Piratvisuth","year":"2013","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.cld.2021.06.004_bib38","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"issue":"11\u201312","key":"10.1016\/j.cld.2021.06.004_bib39","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1365-2036.2010.04474.x","article-title":"Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B","volume":"32","author":"Chan","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"25","key":"10.1016\/j.cld.2021.06.004_bib40","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.3748\/wjg.v20.i25.8195","article-title":"Baseline HBsAg predicts response to pegylated interferon-\u03b12b in HBeAg-positive chronic hepatitis B patients","volume":"20","author":"Chen","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib41","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/hep.24473","article-title":"Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3851\/IMP1887","article-title":"Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-\u03b12b: relation to response and HBV genotype","volume":"17","author":"Sonneveld","year":"2011","journal-title":"Antivir Ther"},{"issue":"3","key":"10.1016\/j.cld.2021.06.004_bib43","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib44","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2021.06.004_bib45","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3851\/IMP1458","article-title":"Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a","volume":"14","author":"Moucari","year":"2009","journal-title":"Antivir Ther"},{"issue":"6","key":"10.1016\/j.cld.2021.06.004_bib46","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jhep.2013.07.017","article-title":"Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype","volume":"59","author":"Brunetto","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2021.06.004_bib47","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.22518","article-title":"Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?","volume":"48","author":"Papatheodoridis","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib48","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib49","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib50","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2021.06.004_bib51","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","article-title":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","volume":"56","author":"Rijckborst","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jcv.2009.07.005","article-title":"Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B","volume":"46","author":"Tangkijvanich","year":"2009","journal-title":"J\u00a0Clin Virol"},{"issue":"6","key":"10.1016\/j.cld.2021.06.004_bib53","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/liv.13046","article-title":"Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B","volume":"36","author":"Chuaypen","year":"2016","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.cld.2021.06.004_bib54","doi-asserted-by":"crossref","first-page":"306.e7","DOI":"10.1016\/j.cmi.2017.07.016","article-title":"Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy","volume":"24","author":"Chuaypen","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"23","key":"10.1016\/j.cld.2021.06.004_bib55","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"TDF disoproxil fumarate versus adefovir Dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.cld.2021.06.004_bib56","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.cld.2021.06.004_bib57","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1111\/liv.14606","article-title":"Hepatitis B surface antigen, core-related antigen and HBV RNA: predicting clinical relapse after NA therapy discontinuation","volume":"40","author":"Kaewdech","year":"2020","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.cld.2021.06.004_bib58","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/apt.13751","article-title":"Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection","volume":"44","author":"Vigan\u00f2","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2021.06.004_bib59","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3390\/ijms22031456","article-title":"Combination of entecavir or TDF with pegylated interferon-\u03b1 for long-term reduction in hepatitis B surface antigen levels: simultaneous, sequential, or add-on combination therapy","volume":"22","author":"Yoshida","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/apt.13440","article-title":"Entecavir safety and effectiveness in a national cohort of treatment-na\u00efve chronic hepatitis B patients in the US \u2013 the ENUMERATE study","volume":"43","author":"Ahn","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of TDF disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.cld.2021.06.004_bib62","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1007\/s10620-018-5251-9","article-title":"Hepatitis B surface antigen loss with TDF disoproxil fumarate plus peginterferon alfa-2a: week 120 analysis","volume":"63","author":"Ahn","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.cld.2021.06.004_bib63","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clinthera.2020.12.022","article-title":"Effect of pegylated interferon plus TDF combination on higher hepatitis B surface antigen loss in treatment-naive patients with hepatitis B e antigen -positive chronic hepatitis B: a real-world experience","volume":"43","author":"Hu","year":"2021","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.cld.2021.06.004_bib64","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/hep.27586","article-title":"Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study)","volume":"61","author":"Brouwer","year":"2015","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib65","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/jvh.12997","article-title":"Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up","volume":"26","author":"van Campenhout","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"issue":"7","key":"10.1016\/j.cld.2021.06.004_bib66","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/infdis\/jix024","article-title":"Pegylated interferon alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos(t)ide analogue: a randomized, controlled trial (PEGON)","volume":"215","author":"Chi","year":"2017","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib67","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/apt.15098","article-title":"Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B","volume":"49","author":"Liem","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib68","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jvh.12999","article-title":"Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B \u2018e\u2019 antigen-negative chronic hepatitis B genotype D","volume":"26","author":"Lampertico","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"issue":"3","key":"10.1016\/j.cld.2021.06.004_bib69","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S2468-1253(16)30189-3","volume":"2","author":"Bourli\u00e8re","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2021.06.004_bib70","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00535-020-01707-6","article-title":"Pilot study of TDF disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B","volume":"55","author":"Matsumoto","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib71","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib72","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350901400405","article-title":"A\u00a0review of the natural history of chronic hepatitis B in the era of transient elastography","volume":"14","author":"Chan","year":"2009","journal-title":"Antivir Ther"},{"issue":"6","key":"10.1016\/j.cld.2021.06.004_bib73","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/0016-5085(92)90337-X","article-title":"A\u00a0controlled trial of interferon with or without prednisone priming for chronic hepatitis B","volume":"102","author":"Lok","year":"1992","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2021.06.004_bib74","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199008023230503","article-title":"A\u00a0randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group","volume":"323","author":"Perrillo","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cld.2021.06.004_bib75","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/gut.2004.060327","article-title":"Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D","volume":"54","author":"Erhardt","year":"2005","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2008.12.019","article-title":"Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B","volume":"51","author":"Zeuzem","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2021.06.004_bib77","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","article-title":"Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response","volume":"5","author":"Chan","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2021.06.004_bib78","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3851\/IMP2580","article-title":"Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-\u03b12a and adefovir","volume":"18","author":"Takkenberg","year":"2013","journal-title":"Antivir Ther"},{"issue":"3","key":"10.1016\/j.cld.2021.06.004_bib79","doi-asserted-by":"crossref","first-page":"218","DOI":"10.7150\/thno.10636","article-title":"Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon","volume":"5","author":"Hou","year":"2015","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.cld.2021.06.004_bib80","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/apt.14862","article-title":"A\u00a0baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B","volume":"48","author":"Chan","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.cld.2021.06.004_bib81","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3851\/IMP3251","article-title":"An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings","volume":"23","author":"Lampertico","year":"2018","journal-title":"Antivir Ther"},{"issue":"2","key":"10.1016\/j.cld.2021.06.004_bib82","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2021.06.004_bib83","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2021.06.004_bib84","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S2468-1253(17)30083-3","article-title":"Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial","volume":"2","author":"de Niet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2021.06.004_bib85","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3851\/IMP3225","article-title":"Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B","volume":"23","author":"Hagiwara","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cld.2021.06.004_bib86","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2147\/IDR.S195144","article-title":"Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus TDF combination therapy in patients with chronic hepatitis B","volume":"12","author":"Zheng","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"7","key":"10.1016\/j.cld.2021.06.004_bib87","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1128\/AAC.00249-15","article-title":"Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.cld.2021.06.004_bib88","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/cid\/ciu702","article-title":"A\u00a0randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B \u201ce\u201d antigen-positive chronic hepatitis B","volume":"59","author":"Xie","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib89","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3851\/IMP3019","article-title":"Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-\u03b12a: 1 year follow-up of the OSST study","volume":"21","author":"Han","year":"2016","journal-title":"Antivir Ther"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib90","doi-asserted-by":"crossref","first-page":"13383","DOI":"10.1038\/s41598-017-13747-9","article-title":"Switching to PegIFN\u03b1-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs","volume":"7","author":"Huang","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.cld.2021.06.004_bib91","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/jvh.12691","article-title":"Hepatitis B surface antigen reduction by switching from long-term nucleoside\/nucleotide analogue administration to pegylated interferon","volume":"24","author":"Tamaki","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"issue":"1","key":"10.1016\/j.cld.2021.06.004_bib92","first-page":"25","article-title":"HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study","volume":"6","author":"Hu","year":"2018","journal-title":"J\u00a0Clin Translational Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2021.06.004_bib93","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s12072-019-09957-0","article-title":"Pegylated-interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non-cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open-label pilot trial","volume":"13","author":"Zhou","year":"2019","journal-title":"Hepatol Int"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326121000544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:57:53Z","timestamp":1761069473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326121000544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1089326121000544"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2021.06.004","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in Treating Chronic HBV","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2021.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}